Lilly’s strong Q1 cushions the blow of FDA thumbs-down on high-dose baricitinib

Lilly’s strong Q1 cushions the blow of FDA thumbs-down on high-dose baricitinib

Source: 
Fierce Pharma
snippet: 

It's been a good news-bad news 24 hours for Eli Lilly. Its closely watched RA prospect baricitinib didn't exactly sail through Monday's FDA committee meeting. But Tuesday morning, Lilly rolled out Q1 results that beat sales and earnings expectations. Upshot? Analysts are still worried about a baricitinib approval.